The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 Ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria

Inflammatory Bowel Diseases

Volumn 12, Issue 11, 2006, Pages 1013-1024

  Carlsen, Hege S ^a,b   Yamanaka, Takeshi ^a   Scott, Helge ^a   Rugtveit, Jarle ^a   Brandtzaeg, Per ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

CD154; CD40; Macrophages; Mucosal immunology; T cells

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CD134 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHLORDANE; CORTICOSTEROID; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLON; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; GASTROINTESTINAL MUCOSA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFLAMMATION; INTESTINE; LAMINA PROPRIA; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMALL INTESTINE; T LYMPHOCYTE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CASE-CONTROL STUDIES; CD40 LIGAND; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPHENOTYPING; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MACROPHAGES; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33750517070     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000234135.43336.72     Document Type: Article

References (41)

1. Danese S, Sans M, Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory bowel disease. Gut. 2004;53:1035-1043.
2. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
3. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
4. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol. 1999;163:4049-4057.
5. Battaglia E, Biancone L, Resegotti A, et al. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am J Gastroenterol. 1999;94:3279-3284.
6. high monocytes in patients with Crohn's disease. Am J Gastroenterol. 2000;95:1516-1523.
7. Polese L, Angriman I, Cecchetto A, et al. The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation. Eur J Gastroenterol Hepatol. 2002;14:237-241.
8. Vogel JD, West GA, Danese S, et al. CD40-mediated immunenonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology. 2004;126:63-80.
9. Gao D, Wagner AH, Fankhaenel S, et al. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut. 2005;54:70-77.
10. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996;183:693-698.
11. De Jong YP, Comiskey M, Kalled SL, et al. Chronic murine colitis is dependent on the CD154/CD40 pathway and can be attenuated by anti-CD154 administration. Gastroenterology. 2000;119:715-723.
12. + T cells by blocking the CD40-CD154 interactions. J Immunol. 2000;164:6005-6014.
13. Li W, Buzoni-Gatel D, Debbabi H, et al. CD40/CD154 ligation is required for the development of acute ileitis following oral infection with an intracellular pathogen in mice. Gastroenterology. 2002;122:762-773.
14. Monk NJ, Hargreaves RE, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med. 2003;9:1275-1280.
15. Dumont FJ. IDEC-131: IDEC/Eisai. Curr Opin Investig Drugs. 2002;3:725-734.
16. Couzin J. Drug discovery: magnificent obsession. Science. 2005;307:1712-1715.
17. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6:114.
18. Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther. 2005;22:111-122.
19. Brandtzaeg P, Baekkevold ES, Morton HC. From B to A the mucosal way. Nat Immunol. 2001;2:1093-1094.
20. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today. 1999;20:267-277.
21. Brandtzaeg P, Johansen FE. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev. 2005;206:32-63.
22. O'Leary AD, Sweeney EC. Lymphoglandular complexes of the colon: structure and distribution. Histopathology. 1986;10:267-283.
23. Surawicz CM, Belic L. Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease. Gastroenterology. 1984;86:104-113.
24. Carlsen HS, Baekkevold ES, Johansen F-E, et al. B cell attracting chemokine 1 (CXCL13) and its receptor CXCR5 are expressed in normal and aberrant gut associated lymphoid tissue. Gut. 2002;3:364-371.
25. Farstad IN, Carlsen H, Morton HC, et al. Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics. Immunology. 2000;101:354-363.
26. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
27. Rugtveit J, Nilsen EM, Bakka A, et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology. 1997;112:1493-1505.
28. Rugtveit J, Bakka A, Brandtzaeg P. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol. 1997;110:104-113.
29. Souza HS, Elia CC, Spencer J, et al. Expression of lymphocyte-endothelial receptor-ligand pairs, a4b7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut. 1999;45:856-863.
30. Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:1931-1936.
31. Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005;115:66-75.
32. Lee BO, Haynes L, Eaton SM, et al. The biological outcome of CD40 signaling is dependent on the duration of CD40 ligand expression: reciprocal regulation by interleukin (IL)-4 and IL-12. J Exp Med. 2002;196:693-704.
33. + T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12. J Immunol. 2000;165:2173-2182.
34. Clegg CH, Rulffes JT, Haugen HS, et al. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol. 1997;9:1111-1122.
35. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5:686-693.
36. + T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med. 2000;191:651-660.
37. Higgins LM, McDonald SA, Whittle N, et al. Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol. 1999;162:486-493.
38. Nolan A, Weiden MD, Hoshino Y, et al. CD40 but not CD154 knockout mice have reduced inflammatory response in polymicrobial sepsis: a potential role for Escherichia coli heat shock protein 70 in CD40-mediated inflammation in vivo. Shock. 2004;22:538-542.
39. Lazarevic V, Myers AJ, Scanga CA, et al. CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M tuberculosis infection. Immunity. 2003;19:823-835.
40. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity. 2001;15:971-983.
41. Whittall T, Wang Y, Kelly CG, et al. Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn's disease. Clin Exp Immunol. 2006;143:550-559.